Preprint / Version 1

Immunotherapy in Non-Small Cell Lung Cancer

##article.authors##

  • Jack Lasner Polygence

DOI:

https://doi.org/10.58445/rars.2000

Keywords:

Immunotherapy, Lung Cancer

Abstract

Cancer is a disease where cells mutate and grow uncontrollably. These cancer cells can even spread to new parts of the body. The immune system, a network of cells, tissues, and organs, fights against infections to protect healthy cells. Ideally, the immune system is supposed to recognize cancer cells as harmful and eliminate them to prevent the cancer from spreading. However, cancer cells can sometimes evade the immune system by hiding, suppressing immune responses, or mimicking normal cells by altering the expression of certain proteins on their surface. Immunotherapy is a type of treatment that utilizes the immune system to fight cancer. Rather than targeting all cells indiscriminately, as traditional treatments like chemotherapy and radiation often do, immunotherapy strengthens your immune system to better recognize and terminate cancer cells. This unique approach makes immunotherapy an attractive option to overcome cancer’s ability to evade immune responses. This review examines current immunotherapy treatments and future directions for non-small cell lung cancer (NSCLC) treatment.

References

Clark, Shane B., and Saud Alsubait. “Non–Small Cell Lung Cancer.” StatPearls [Internet]., U.S. National Library of Medicine, 4 Sept. 2023, www.ncbi.nlm.nih.gov/books/NBK562307/.

Chevallier, Mathieu, et al. “Oncogenic Driver Mutations in Non-Small Cell Lung Cancer: Past, Present and Future.” World Journal of Clinical Oncology, U.S. National Library of Medicine, 24 Apr. 2021, pmc.ncbi.nlm.nih.gov/articles/PMC8085514/.

Cleveland Clinic. “Non-Small Cell Lung Cancer (NSCLC): Causes, Symptoms & Treatment.” Cleveland Clinic, 1 May 2024, my.clevelandclinic.org/health/diseases/6203-non-small-cell-lung-cancer#:~:text=Outlook%20%2F%20Prognosis&text=This%20means%20that%2063%25%20of,year%20survival%20rate%20is%207%25.

Stanley, Robyn, et al. “Immunotherapy through the Lens of Non-Small Cell Lung Cancer.” Cancers, U.S. National Library of Medicine, 30 May 2023, pmc.ncbi.nlm.nih.gov/articles/PMC10252117/.

Anichini, Andrea, et al. “Immune Escape Mechanisms in Non Small Cell Lung Cancer.” Cancers, U.S. National Library of Medicine, 2 Dec. 2020, pmc.ncbi.nlm.nih.gov/articles/PMC7761620/.

The Fourth Affiliated Hospital of Zhejiang University School of Medicine. “Combined Statin and PD-1/​PD-L1 Inhibitors in Treating Non-Small Cell Lung Cancer.” Clinicaltrials.Gov, 15 Oct. 2022, clinicaltrials.gov/study/NCT05636592?cond=NSCLC&intr=Immunotherapy&aggFilters=status%3Aact&rank=1.

Guangdong Provincial People’s Hospital. “Neoadjuvant Immunotherapy in EGFR-Mutant Localized NSCLC (NEOTIDE).” Clinicaltrials.Gov, 4 June 2022, clinicaltrials.gov/study/NCT05244213?cond=NSCLC&intr=Immunotherapy&aggFilters=status%3Aact&rank=7.

Downloads

Posted

2024-11-19

Categories

License

Copyright (c) 2024 Jack Lasner

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license